STAT

JUNE 5, 2024

” Here is the back story: In 2001, Gilead won U.S. For its part, the company issued a statement in which it did not admit wrongdoing and continued to maintain it has “never stopped working to improve the lives of people with HIV.”

358

358

STAT

JUNE 15, 2023

The Centers for Disease Control and Prevention report examined the homicide and suicide rates among 10- to 24-year-olds from 2001 to 2021. The homicide rate for older U.S. Read the rest…

242

242

STAT

AUGUST 8, 2023

The study, published last week in The Lancet Psychiatry , analyzed answers that participants provided between 2001 and 2022 in response to a World Health Organization survey designed to assess the prevalence of major mental health disorders.

246

246

Pharmaceutical Technology

NOVEMBER 18, 2024

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.

52

52

European Pharmaceutical Review

OCTOBER 19, 2023

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.

105

105

STAT

MARCH 31, 2023

Indeed, academic inventors or founders contributed to more than one-quarter of all medicines approved from 2001 through 2019. Academia can be an excellent source of novel drug targets and new technologies that can enhance medicinal discovery. Yet many sponsored research collaborations that hope to tap into academia fail.

Drug Development 250

Drug Development 250

STAT

JANUARY 10, 2023

Five studies co-authored by Tessier-Lavigne are now under the microscope for containing alleged altered images: a 1999 Cell study , a 2008 paper in the EMBO Journal, a 2003 Nature study, and two studies published in 2001 in Science.

326

326

STAT

FEBRUARY 13, 2024

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage.

Drug Development 286

Drug Development 286

STAT

DECEMBER 12, 2022

The deal is the largest pharma merger announced this year, and it represents the most that Amgen has spent on an acquisition since its $16 billion purchase of Immunex in 2001. Amgen said Monday it would purchase Horizon Pharmaceuticals for $27.8 Continue to STAT+ to read the full story…

Pharmaceutical Companies 242

Pharmaceutical Companies Pharmaceutical Companies 242

STAT

JANUARY 31, 2023

The program is widely considered a success and has worked well for many drugs, including the leukemia drug Gleevec , which the FDA approved in 2001 after a review period of just two-and-a-half months, based on study results that correctly predicted successful clinical outcomes. Continue to STAT+ to read the full story…

Drug Pricing 238

Drug Pricing 238

STAT

AUGUST 31, 2023

The retractions come the same day that Tessier-Lavigne’s resignation as Stanford president takes effect.

345

345

STAT

JULY 17, 2023

The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001.  But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease.

240

240

EMCrit Project

SEPTEMBER 28, 2023

Major interest in tight glycemic control in the ICU began in 2001 with an RCT by the same group of investigators, also […] EMCrit Project by Josh Farkas. background Today the Van de Bergh group in Belgium released a RCT investigating tight versus liberal glycemic control in the ICU.

120

120

Outsourcing Pharma

JULY 26, 2023

Leslie Orne joined Trinity Life Sciences in 2001 and was recently appointed CEO and president of the fast-growing healthcare consultancy. She previously held the title of chief commercial officer (CCO) and president.

81

81

STAT

DECEMBER 12, 2022

The deal is the largest pharmaceutical merger announced this year, and it represents the most that Amgen has spent on an acquisition since its $16 billion purchase of Immunex in 2001. The The product is expected to generate $1.97 billion in 2022 and $2.26 billion in 2023, according to FactSet, an investment data firm.

239

239

STAT

APRIL 11, 2024

stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country, STAT tells us. Unresolved The number of ongoing and active drug shortages in the U.S.

Chemotherapy 232

Chemotherapy Immunization Immunity 232

Pharmacy Times

MAY 8, 2024

Ongoing and active shortages are currently at the highest number since January 2001.

52

52

Pharmaceutical Technology

JULY 10, 2023

The US FDA has granted orphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.

52

52

ALiEM - Pharm Pearls

SEPTEMBER 30, 2024

2001 Dec;59(12):1462-70. However, non-traumatic hyphema should prompt investigation for hematologic disorders such as Sickle cell disease. References Brandt MT, Haug RH. Traumatic hyphema: a comprehensive review. J Oral Maxillofac Surg. doi: 10.1053/joms.2001.28284. 2001.28284. PMID: 11732035. Gragg J, Blair K, Baker MB. 2022 Dec 26.

161

161

NY Times

DECEMBER 2, 2021

In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. That preceded an ambitious global campaign to curb the virus. How well did it work?

Immunization 59

Immunization Immunity 59

Express Pharma

JANUARY 22, 2024

The drugmaker received funding to develop the RTS,S-based vaccine for young children in 2001, it said. The vaccine has been in the making for nearly 40 years. It was first created in 1987, according to GSK.

Vaccines 104

Vaccines 104

European Pharmaceutical Review

NOVEMBER 11, 2022

NTLA-2001, a novel CRISPR/Cas9-based therapy in the first-ever human gene editing trial ( NCT04601051 ) in vivo (in the body), reduced transthyretin (TTR) proteins by at least 90 percent in amyloidogenic transthyretin (ATTR) cardiomyopathy patients, 28 days after a single IV infusion, with benefits lasting four to six months.

Labelling 118

Labelling Hospitals 118

pharmaphorum

JUNE 28, 2021

Preliminary results from a phase 1 trial run by Regeneron and CRISPR specialist Intellia Therapeutics – co-founded by Nobel Prize winner Jennifer Doudna – showed steep reductions in a biomarker of ATTR amyloidosis disease activity with a single dose of the NTLA-2001 drug.

Packaging 103

Packaging 103

pharmaphorum

DECEMBER 1, 2022

Led by the MPE CEE Workgroup on Access, the report – Addressing access barriers to myeloma clinical trials in Central and Eastern Europe – evaluated the number of clinical trials held in CEE countries between 1 January 2001 and 28 September 2020. Approximately 50,000 people in Europe are diagnosed with myeloma each year.

72

72

FDA Law Blog: Biosimilars

MAY 3, 2023

Before joining HP&M in 2001, Mr. Houck conducted numerous scheduled cyclic and targeted inspections and investigations as a DEA Diversion Investigator in the field for ten years. Registrants are far from powerless when DEA investigators inspect their controlled substance operations.

Controlled Substances 52

Controlled Substances 52

RX Note

JUNE 13, 2023

External Links Clinical Inertia and Outpatient Medical Errors Clinical inertia, 2001 Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review, 2020

Clinic Management 52

Clinic Management Communication Diabetes 52

FDA Law Blog: Biosimilars

SEPTEMBER 12, 2023

In this webinar you’ll learn: How employees diverted controlled substances — their methods are constantly evolving What red flags were missed DEA inspection priorities Safeguards to minimize internal diversion Best practices for maximizing diversion detection Mr. Houck was a DEA Diversion Investigator for 15 years prior to joining HPM in 2001.

Controlled Substances 48

Controlled Substances Hospitals 48

PharmaShots

MAY 3, 2023

Additionally, high-throughput CRISPR editing is used by Artisan's SyionAI platform for novel drug discovery Ref: PR Newswire | Image: BrightPath Biotherapeutics Related News:- REGiMMUNE Entered into a License Agreement with San Fu Biotech to Develop and Commercialize RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease

40

40

pharmaphorum

JANUARY 6, 2022

H3B-8800 – now renamed RVT-2001 – will be taken in a slightly different direction by Roivant, which said it plans to develop it as a therapy for transfusion-dependent anaemia in patients with lower-risk MDS, according to the company.

Compounding 52

Compounding Drug Development 52

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2023

In this webinar you’ll learn: How employees diverted controlled substances — their methods are constantly evolving What red flags were missed DEA inspection priorities Safeguards to minimize internal diversion Best practices for maximizing diversion detection Mr. Houck was a DEA Diversion Investigator for 15 years prior to joining HPM in 2001.

Controlled Substances 44

Controlled Substances Hospitals 44

Pharmacy Joe

JANUARY 24, 2024

For example, if the new article is about glucose control in the ICU, you can be sure that the letter to the editor will mention other landmark trials such as 2001 article by Van Den Berghe and NICE-SUGAR.

Inpatient 98

Inpatient Hospitals 98

FDA Law Blog: Biosimilars

MAY 22, 2023

Before joining HP&M in 2001, Mr. Houck conducted numerous scheduled cyclic and targeted inspections and investigations as a DEA Diversion Investigator in the field for ten years. Registrants are far from powerless when DEA investigators inspect their controlled substance operations.

Controlled Substances 40

Controlled Substances 40

RX Note

JUNE 11, 2023

External Links UpToDate - Paronychia Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid, 2001 Acute felon and paronychia: Antibiotics not necessary after surgical treatment. Refractory chronic paronychia - consider surgical intervention.

Diabetes 52

Diabetes Community Pharmacies 52

European Pharmaceutical Review

JANUARY 25, 2024

Proposal for a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC.” References European Commission, (26 April 2023). Article 63 EMA (29 January 2020). Article 63 Euractiv (26 September 2023).

Packaging 98

Packaging Documentation Communication Pharmaceutical Companies 98

RX Note

JULY 16, 2023

External Links A randomized, controlled clinical trial of four anti-dandruff shampoos, 1981 Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments, 2001 A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic (..)

Community Pharmacies 52

Community Pharmacies 52

European Pharmaceutical Review

JUNE 24, 2022

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. One of the key priorities of the EU’s strategy is to encourage innovation to solve unmet medical needs. Brussels; 2020.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

Pharmacy Is Right For Me

OCTOBER 21, 2022

I worked in Dallas from 95-2001, then moved to NYC, then years later went to the University of Colorado for the NTPD program and received the PharmD. What makes your career path unique?  My focus in Pharmacy School at OU was Nuclear Medicine. There was a fully operational Nuclear Pharmacy on campus, and I took all the courses.

Hospitals 130

Hospitals Labelling Vaccines Drug Development 130